Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES DOMINION BIOLOGICALS RECEIVES FDA NOTIFICATION OF FINAL SITE INSPECTION FOR NOVACLONE(TM) PRODUCTS

INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES DOMINION BIOLOGICALS RECEIVES FDA NOTIFICATION OF FINAL SITE INSPECTION FOR NOVACLONE(TM) PRODUCTS
 TORONTO, Ontario, Dec. 9 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) announced today that the U.S. Food and Drug Administration (FDA) will inspect Dominion Biologicals Limited's Dartmouth, Nova Scotia manufacturing facility on Dec. 10 and 11.
 The FDA site inspection is in connection with Dominion's product and facility license application for its NovaClone(TM) line of monoclonal antibody based blood typing reagents.
 Dominion, the dominant supplier of blood bank reagents in Canada, intends to begin selling the NovaClone(TM) product line in the U.S. and other countries requiring FDA approval in 1992. NovaClone(TM) products are manufactured in Dartmouth using Dominion's proprietary bioreactor system and internally developed hybridoma cell lines.
 The NovaClone(TM) monoclonal based reagents exhibit greater accuracy, ease of use and lot-to-lot consistency than conventional polyclonal based reagents which are derived from human blood. Because these products are not manufactured using human blood, the possibility of infecting manufacturing personnel or end-users is eliminated. Also, these monoclonal products are less expensive to manufacture than the polyclonal based reagents and therefore will generate higher gross margins.
 Dominion and its sister company, Murex Biologicals (formerly Amtec Diagnostics International) of Conroe, Texas, manufacture and market 55 FDA approved blood typing and grouping reagents. Dominion and Murex Biologicals' products are sold directly by their sales forces in the U.S. and Canada and abroad through an established distribution network. These products will soon be marketed worldwide through Wellcome Diagnostics' distribution network.
 Toronto-based MXX is an international medical diagnostic systems company dedicated to the development, manufacture and global marketing of cost-effective diagnostic tests for infectious diseases and products for the blood banking industry.
 -0- 12/9/91
 /CONTACT: C. Robert Cusick, president and chief executive officer, or Marcia M. Young, 800-688-1332 or 416-408-4682, of International Murex Technologies/
 (MXX) CO: International Murex Technologies Corporation; Dominion Biologicals
 Limited ST: Ontario IN: MTC SU:


CF-BR -- AT003 -- 0405 12/09/91 09:05 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1991
Words:336
Previous Article:SUNRISE MEDICAL ACQUIRES HEALTH PRODUCTS INC., AIR FLOATATION THERAPY PRODUCTS COMPANY
Next Article:TSI ANNOUNCES FINANCING INTENTION, CONVERTIBILITY OF PREFERRED STOCK
Topics:


Related Articles
INTERNATIONAL MUREX REPORTS NOTIFICATION OF 13-D FILING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES THIRD QUARTER RESULTS
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES PRICING OF EURO-EQUITY FINANCING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES COMPLETION OF THE PURCHASE OF WELLCOME DIAGNOSTICS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES DIVESTITURE OF ITS BLOOD TYPING AND GROUPING REAGENT BUSINESS
BRITISH COURT RULES ON HEPATITIS C PATENT; MUREX CONTINUES TO SELL ANTI-HCV PRODUCTS
INTERNATIONAL MUREX PROMOTES J. DAVID THOLEN TO CHIEF EXECUTIVE OFFICER
INTERNATIONAL MUREX LICENSES TECHNOLOGY TO ABBOTT LABORATORIES
Immucor Acquires Canada's Dominion Biologicals Limited
International Murex Reports First Quarter Earnings of $0.10 Per Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters